University Of Maryland, Baltimore
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1807-01-01
- Employees
- 7.3K
- Market Cap
- -
- Website
- http://www.umaryland.edu
Adjunctive Treatment for Decreasing Symptoms of Schizophrenia
- Conditions
- SchizophreniaSchizoaffective Disorder
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 240
- Registration Number
- NCT00222235
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States
🇮🇱Ezrath Nashim Association, Sarah Herzog Memorial Hospital, Jerusalem, Israel
🇺🇸UCLA/VA Greater Los Angeles Health Care System, Los Angeles, California, United States
A Comparison of Bupropion SR and Placebo for Smoking Cessation
- Conditions
- Tobacco Use Disorder
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 52
- Registration Number
- NCT00176449
- Locations
- 🇺🇸
Maryland Psychiatric REsearch Center, Catonsville, Maryland, United States
Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
- Conditions
- Schizophrenia
- Interventions
- Behavioral: Diet support groupBehavioral: Group counseling and exercise
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2022-03-14
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 40
- Registration Number
- NCT00176436
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 117
- Registration Number
- NCT00176423
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States
New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 150
- Registration Number
- NCT00161018
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 30
- Registration Number
- NCT00161031
- Locations
- 🇺🇸
Veterans Affairs Maryland Health Care System, Baltimore, Maryland, United States
🇺🇸Maryland Psychiatric Research Center, Catonsville, Maryland, United States
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
- Conditions
- Chronic Schizophrenia
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 20
- Registration Number
- NCT00161044
- Locations
- 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States
Electrophysiological Effects of Late PCI After MI
- Conditions
- Cardiovascular DiseasesHeart DiseasesMyocardial InfarctionCoronary DiseaseArrhythmiaVentricular Fibrillation
- Interventions
- Procedure: PCIDrug: Optimal Medical Therapy
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 300
- Registration Number
- NCT00119847
- Locations
- 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States
Improving Cardiovascular Treatment Approaches Among Minorities
- Conditions
- Cardiovascular DiseasesHypertensionHeart DiseasesDiabetes Mellitus
- First Posted Date
- 2005-01-11
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 823
- Registration Number
- NCT00101478
- Locations
- 🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States
🇺🇸Bon Secours Hospital, Baltimore, Maryland, United States
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- First Posted Date
- 2004-08-27
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00004009
- Locations
- 🇺🇸
University of Iowa College of Medicine, Iowa City, Iowa, United States
🇺🇸University of Rochester Cancer Center, Rochester, New York, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States